Education
About Us
Working with TipRanks
Follow Us
Evoke Pharma (EVOK)
NASDAQ:EVOK
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.33Last Year’s EPS
-2.04Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: -27.34%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, increased prescription fulfillment, and strategic partnerships, contributing to a positive financial outlook for 2025. Despite a net loss and increased expenses, the overall sentiment remains optimistic, bolstered by clinical validation and a strong cash position.Company Guidance
During the Evoke Pharma, Inc. Fourth Quarter and Full Year 2024 Earnings Conference Call, the company reported strong financial results with total revenue reaching $10.2 million for the year, marking a 97% year-over-year increase. The fourth-quarter revenue was $3.3 million, a 24.6% sequential increase. Significant growth drivers included a 46% increase in prescribers, expanding the cumulative prescriber base to 2,553, and a 72% increase in fill rates. Furthermore, patient enrollments grew by 22%. The company also highlighted the role of its strategic partnership with Aspen pharmacies, contributing to a 30% faster speed to therapy and a substantial reduction in out-of-network prescriptions. Looking forward, Evoke Pharma projects a 60% increase in net revenue for 2025, aiming for approximately $16 million, driven by enhanced reimbursement pathways and increased prescription fills. The company emphasized its commitment to strengthening market position through expanding pharmacy partnerships and increasing provider engagement.Record Revenue Growth
Evoke Pharma, Inc. reported a 97% year-over-year increase in revenue, reaching $10.2 million for 2024, up from $5.2 million in 2023.
Increased Prescription Fulfillment
The company achieved a 72% increase in fill rates year over year and a 22% growth in patient enrollments.
Expansion of Prescriber Base
There was a 46% increase in prescribers year over year, bringing the total cumulative prescriber base to 2,553.
Strategic Pharmacy Partnerships
Partnership with Aspen pharmacies facilitated faster delivery and insurance adjudication, contributing to commercial success.
Positive Financial Outlook
Projected net revenue guidance for 2025 is approximately $16 million, representing a 60% increase over 2024.
Strong Cash Position
Cash and cash equivalents were approximately $13.6 million as of December 31, 2024, with a cash runway into the first quarter of 2026.
Clinical Validation and Awards
Gimoti received the presidential poster award at ACT 2024 and demonstrated significant improvement over oral metoclopramide in real-world data.
---
EVOK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EVOK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $3.84 | $3.82 | -0.52% |
| Nov 07, 2024 | $5.65 | $5.65 | 0.00% |
| Aug 13, 2024 | $5.69 | $5.74 | +0.88% |
| May 14, 2024 | $5.64 | $5.62 | -0.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Evoke Pharma (EVOK) report earnings?
Evoke Pharma (EVOK) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is Evoke Pharma (EVOK) earnings time?
Evoke Pharma (EVOK) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVOK EPS forecast?
EVOK EPS forecast for the fiscal quarter 2025 (Q1) is -0.33.
---